Back to results
US 2026/0242398 A1Published application
Benzopyrimidin-4(3h)-ones as pi3k inhibitors
AssigneeOnKure, Inc.
InventorsJames F. Blake, Mark Laurence Boys, David A. Mareska, Joshua Nathaniel Payette, Christie A. Schulte, Bryan Yestrepsky, Qian Zhao
Life of this patent
Estimating the term…
Abstract
Novel PI3K inhibitors of the general Formula (1) are described along with methods of their preparation and their use in the treatment of diseases associated with the elevation or activation of the PI3K pathway, wherein R1 to R8 are as defined.
Claims21
-37. (canceled)
A compound of Formula (1)
- or a solvate, enantiomer, diastereomer, tautomer, polymorph or isotope-labeled compound,
- or a pharmaceutically acceptable salt thereof,
- wherein:
- R1 is H, C1-C4 alkyl or C3-C7 cycloalkyl;
- each R2 is independently H, C1-C4 alkyl, C3-C7 cycloalkyl, R14—C≡C—, halogen, CN, CF3, OCF3, CFH2 or CF2H;
- R3 is H, C1-C4 alkyl, C3-C7 cycloalkyl, CF3, CFH2 or CF2H, and where R3 is not H, the carbon atom attached to R3 is a chiral center and exists as a (R)- and (S)-racemic mixture or as either the (R)- or (S)-enantiomer;
- R4 is H or C1-C4 alkyl;
- R6 is H, C1-C4 alkyl, C3-C7 cycloalkyl, heteroaryl, CF3, CFH2 or CF2H;
- R7 is H, C1-C4 alkyl, C3-C7 cycloalkyl, halogen, CN, CF3, OCF3, OCH3, CFH2 or CF2H;
- R8 is H, C1-C4 alkyl, C3-C7 cycloalkyl, halogen, CN, CF3, OCF3, OCH3, CFH2 or CF2H;
- R5 is
- wherein:
- each of L1, L2, L3, L6 and L7 is independently (CHR11), (CHR11—O), (CHR11—S), (C3-C7 cycloalkyl) or a bond;
- L4 is C═O, C═S or a bond;
- L5 is NR10, S, O or a bond;
- R9 is H, C(═O)R12, C(═O)NR12R13, C(═O)OR12, C1-C6 alkyl, C1-C6 fluoroalkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl, where each of the C1-C6 alkyl, C1-C6 fluoroalkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl is unsubstituted or substituted, or alternatively when NR10 is present, R9 and R10 together with the attached nitrogen atom may form a 4-7 membered non-aromatic heterocyclic ring, where the ring may contain additional heteroatoms and is substituted or unsubstituted;
- each of R10 and R11 is H or C1-C4 alkyl, where the C1-C4 alkyl is unsubstituted or substituted;
- and
- each of R12 and R13 is independently H or C1-C6 alkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl, where each of the C1-C6 alkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl is unsubstituted or substituted or alternatively, R12 and R13 together with the attached nitrogen atom together with the attached nitrogen atom may form a 4-7 membered non-aromatic heterocyclic ring, where the ring may contain additional heteroatoms and is substituted or unsubstituted;
- each R14 is independently H, C1-C3 alkyl or C3-C7 cycloalkyl;
- or R5 is
- a non-aromatic N-linked heterocyclic ring
- where the heterocyclic ring is substituted or unsubstituted, optionally contains one or more additional atoms selected from N (where the N is substituted or unsubstituted), O, Si (where the Si is substituted or unsubstituted) and S (where the S is oxidized or unoxidized), and is optionally part of a bridged, fused or spiro ring system.
20 more elements
Dependencies are inferred from the claim text.